Cancer最新文献

{"title":"Advancing trial recruitment science through enhanced study design","authors":"Patrick Lewicki MD, MS, Kristian Stensland MD, MPH, MS","doi":"10.1002/cncr.35703","DOIUrl":"10.1002/cncr.35703","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of obesity on outcome in children diagnosed with cancer in Canada: A report from Cancer in Young People in Canada","authors":"Samuel Sassine MD, MSc,&nbsp;André P. Ilinca MD,&nbsp;Hallie Coltin MD, MSc,&nbsp;Henrique Bittencourt MD, PhD,&nbsp;Uma Athale MD,&nbsp;Lynette Bowes MD,&nbsp;Josée Brossard MD,&nbsp;Sara Israels MD,&nbsp;Donna L. Johnston MD,&nbsp;Ketan Kulkarni MD,&nbsp;Sarah McKillop MD,&nbsp;Meera Rayar MD,&nbsp;Roona Sinha MD,&nbsp;Tony Truong MD, MPH,&nbsp;Catherine Vézina MD,&nbsp;Laura Wheaton MD,&nbsp;Alexandra P. Zorzi MD,&nbsp;Lillian Sung MD, PhD,&nbsp;Marie-Claude Pelland-Marcotte MD, PhD,&nbsp;Thai Hoa Tran MD","doi":"10.1002/cncr.35673","DOIUrl":"10.1002/cncr.35673","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Childhood obesity can result in adverse health outcomes. The objectives of this study were to describe the prevalence of obesity and determine the association between obesity at cancer diagnosis and event-free survival (EFS) and overall survival (OS) in children diagnosed with cancer in Canada.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The authors conducted a retrospective cohort study using the Cancer in Young People in Canada database, including all children with newly diagnosed cancer aged 2–18 years across Canada from 2001 to 2020. Obesity was defined as age-adjusted and sex-adjusted body mass index greater than or equal to the 95th percentile. Univariate and multivariable Cox proportional hazards models compared EFS and OS between patients with and without obesity at diagnosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In total, 11,291 patients were included, of whom 10.5% were obese at diagnosis. In multivariable models controlling for age, sex, ethnicity, neighborhood income quintile, treatment era, and cancer categories, obesity at diagnosis was independently associated with inferior EFS (adjusted hazard ratio [aHR], 1.16; 95% confidence interval [CI], 1.02–1.32; <i>p</i> = .02) and OS (aHR, 1.29; 95% CI, 1.11–1.49; <i>p</i> = .001). The adverse prognostic impact of obesity was particularly notable for acute lymphoblastic leukemia (ALL) and central nervous system (CNS) tumors. In children with ALL (<i>n</i> = 3458), obesity remained associated with inferior EFS (aHR, 1.55; <i>p</i> = .002) and OS (aHR, 1.75; <i>p</i> = .002) in multivariable analysis. In patients with CNS tumors (<i>n</i> = 2458), obesity was also associated with inferior EFS (aHR, 1.38; <i>p</i> = .008) and OS (aHR, 1.47; <i>p</i> = .004).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In this population-based study, obesity at cancer diagnosis was independently associated with inferior survival across the entire cohort, and prominently in children with ALL and CNS tumors.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of focal anaplastic Wilms tumor: A report from the Children's Oncology Group AREN0321 and AREN03B2 studies","authors":"Amy E. Armstrong MD,&nbsp;Najat C. Daw MD,&nbsp;Lindsay A. Renfro PhD,&nbsp;James I. Geller MD,&nbsp;John A. Kalapurakal MD,&nbsp;Geetika Khanna MD,&nbsp;Arnold C. Paulino MD,&nbsp;Elizabeth J. Perlman MD,&nbsp;Peter F. Ehrlich MD,&nbsp;Kenneth W. Gow MD,&nbsp;Anne B. Warwick MS, MD, MPH, MSS, Colonel,&nbsp;Paul E. Grundy MD,&nbsp;Conrad V. Fernandez MD,&nbsp;Elizabeth A. Mullen MD,&nbsp;Jeffrey S. Dome MD, PhD,&nbsp;the Children's Oncology Group AREN0321 and AREN03B2 Study Committees","doi":"10.1002/cncr.35713","DOIUrl":"10.1002/cncr.35713","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>In the fifth National Wilms Tumor Study, patients received vincristine and dactinomycin (VA) without radiation for stage I focal anaplastic Wilms tumor (FAWT) and VA plus doxorubicin (DD4A) and radiation for stage II–IV FAWT. Four-year event-free survival (EFS) and overall survival (OS) for stage I FAWT were 67.5% and 88.9% and for stage IV FAWT were 61.4% and 71.6%, respectively. Therapy intensification for stage I and IV FAWT was evaluated as secondary objectives in AREN0321.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Central review in the AREN03B2 Renal Tumors Classification, Biology, and Banking Study confirmed patient stage and tumor histology. Patients were then enrolled in AREN0321 and received DD4A with radiation for stage I–III FAWT and vincristine, doxorubicin, cyclophosphamide, carboplatin, and etoposide (UH-1/revised UH-1) with radiation for stage IV FAWT. Outcomes of patients with FAWT who were treated in AREN0321 (<i>n</i> = 25) and in AREN03B2 (<i>n</i> = 20) treated as per AREN0321 were analyzed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the pooled data analysis from AREN0321 and AREN03B2, 4-year EFS and OS were both 100% for stage I–II FAWT (<i>n</i> = 21), 82.4% (95% CI, 66.1%–100%) and 87.8% (95% CI, 73.4%–100%) for stage III FAWT (<i>n</i> = 17), respectively, and both 85.7% (95% CI, 63.3%–100%) for stage IV FAWT (<i>n</i> = 7). Four patients enrolled in AREN0321 had events: treatment failure occurred in three patients with stage III FAWT, and one treatment-related death was observed in a patient with stage IV FAWT following revised UH-1. No EFS or OS events occurred in patients with FAWT enrolled in AREN03B2 only.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Patients with stage I and II FAWT have outstanding survival when treated with DD4A and radiation. Intensification of therapy may have improved survival for stage IV FAWT, albeit with an increased toxicity risk.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Measuring the impact of a catchment area surveillance tool on cancer center adopters","authors":"Todd Burus MAS,&nbsp;Caree R. McAfee MA, CHES,&nbsp;Natalie P. Wilhite MA,&nbsp;Pamela C. Hull PhD","doi":"10.1002/cncr.35710","DOIUrl":"10.1002/cncr.35710","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The University of Kentucky Markey Cancer Center developed the data gathering and visualization platform Cancer InFocus (CIF) as a solution for cancer center catchment area surveillance. CIF was released in June 2022 and made available for use to other institutions through a no-cost licensing agreement. The purpose of this study was to evaluate the impact CIF has had on cancer centers since its release.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The authors adapted an existing management evaluation framework to assess the impact of CIF across three spheres—idea dissemination, product engagement, and adopter satisfaction. This assessment included an online survey administered between the dates of September 18, 2023 and June 22, 2024 among 28 individuals at 13 CIF adopting institutions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>As of October 2024, the ideas and approaches of CIF had been disseminated with national audiences 13 times and featured in one peer-reviewed publication. Thirty-five institutions, including 26 National Cancer Institute–Designated Cancer Centers, had engaged in licensing CIF. In a user satisfaction survey among adopting institutions, a majority of individuals indicated they were gathering more data (91.7%) and requiring less effort to disseminate data (72.0%) using CIF than under their previous methods.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>CIF has demonstrated a broad and positive impact on cancer center catchment area surveillance in the 2 years since its release. CIF represents a high value, low-cost option for cancer centers wanting to build a cancer surveillance dashboard. The framework used for evaluating CIF's impact can be adapted to assess the impact of other open-source software built and distributed by cancer centers.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11725053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to “De-escalation of axillary surgery in patients with sentinel lymph node micrometastases after neoadjuvant systemic therapy”","authors":"Dong Seung Shin MD,&nbsp;Jai Min Ryu MD, PhD,&nbsp;Se Kyung Lee MD, PhD,&nbsp;Jonghan Yu MD, PhD,&nbsp;Jeong Eon Lee MD, PhD,&nbsp;Seok Won Kim MD, PhD,&nbsp;Seok Jin Nam MD, PhD,&nbsp;Byung Joo Chae MD, PhD","doi":"10.1002/cncr.35699","DOIUrl":"10.1002/cncr.35699","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"De-escalation of axillary surgery in patients with sentinel lymph node micrometastases after neoadjuvant systemic therapy","authors":"Mariam Rizk MD,&nbsp;Kefah Mokbel MBBS, MS, FRCS","doi":"10.1002/cncr.35698","DOIUrl":"10.1002/cncr.35698","url":null,"abstract":"","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142968817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A national estimate of mental disorders and mortality outcomes in cancer survivors","authors":"Thi Xuan Mai Tran PhD,&nbsp;Min Sung Chung MD, PhD,&nbsp;Chihwan Cha MD,&nbsp;Boyoung Park MD, PhD","doi":"10.1002/cncr.35711","DOIUrl":"10.1002/cncr.35711","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This study evaluated the prevalence of various mental disorders and their influence on mortality outcomes in individuals with cancer.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The authors' institutional database included patients with cancer diagnosed between 2011 and 2015 who had mental disorders and death information up to 2021. Mental disorders included nonaffective psychotic disorders, affective psychotic disorders, anxiety-related and stress-related disorders, alcohol or drug misuse, and mood disorders without psychotic symptoms. The causes of death were classified as all-cause, cancer-related, or suicide. Individual matching was performed to randomly match cancer survivors with and without mental disorders according to age at cancer diagnosis, year of cancer diagnosis, sex, and cancer site. The association between mental disorders and mortality risk was assessed using a Cox proportional hazards model and competing-risk analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 637,491 cancer survivors (mean age, 58.9 years), there were 238,654 deaths from any cause and 2255 deaths from suicide. Incidence rates varied across disorders, with the highest rates observed for anxiety-related and stress-related disorders and mood disorders without psychotic symptoms. Mental disorders were associated with an increased risk of all-cause and cancer-related mortality. Adjusted hazard ratios (HRs) for nonaffective psychotic disorders, affective psychotic disorders, anxiety-related and stress-related disorders, alcohol and drug misuse, and mood disorders without psychotic symptoms were as follows: HR, 2.49 (95% confidence interval [CI], 2.22–2.80); HR, 2.38 (95% CI, 2.21–2.57); HR, 1.02 (95% CI, 1.01–1.04); HR, 2.13 (95% CI, 1.87–2.43); and HR, 1.27 (95% CI, 1.24–1.30), respectively, for all-cause mortality. Suicide risk was higher in patients who had mental disorders, especially within the first 6 months after diagnosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The current findings underscore the impact of mental illness on mortality among cancer survivors in Korea, specifically highlighting the elevated rates of anxiety, stress, and mood disorders.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of female-specific cancers in China from 1990 to 2021: A systematic analysis for the Global Burden of Disease Study 2021","authors":"Wenhui Ren PhD,&nbsp;Xiangyu Guo MM,&nbsp;Zheng Liu MPH,&nbsp;Yanqiu Wu MEng,&nbsp;Rui Peng MM,&nbsp;Huixin Liu PhD,&nbsp;Jinlei Qi PhD","doi":"10.1002/cncr.35712","DOIUrl":"10.1002/cncr.35712","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Breast cancer and reproductive system cancers remain significant public health threats for Chinese women. This study aimed to evaluate the latest epidemiological patterns and trends of four female-specific cancers in China.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The year- and age-specific estimates of the incidence, mortality, and disability-adjusted life-years (DALYs) associated with breast, cervical, ovarian, and uterine cancers in China from 1990 to 2021 were generated from the Global Burden of Disease, Injuries, and Risk Factors 2021 study. The epidemiological characteristics were analyzed with age–period–cohort models. A Bayesian age–period–cohort model was applied to forecast disease burden from 2022 to 2050.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;In 2021, China reported 385.84 thousand (95% uncertainty interval [UI], 294.10–489.01 thousand) incident cases of female breast cancer, followed by cervical cancer (132.79 thousand [95% UI, 95.96–172.60 thousand]), uterine cancer (72.02 thousand [95% UI, 53.31–100.00 thousand]), and ovarian cancer (41.24 thousand [95% UI, 30.30–54.55 thousand]). Breast cancer ranked as the primary cause of cancer-related deaths, followed by cervical cancer. The age-specific incidence rate for breast, cervical, ovarian, and uterine cancers are projected to occur in the age groups 60–64 years, 55–59 years, 65–69 years, and 60–64 years, respectively. Breast, ovarian, and uterine cancer cases are projected to rise by 2050, which will exceed those recorded in 2021.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Various inequities have been identified across four types of cancers affecting women, which underscores the need for tailored national cancer control strategies. Emphasis should be placed on primary prevention and screening for breast and cervical cancers, whereas efforts for uterine and ovarian cancers should focus on implementing early diagnosis and treatment measures.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Plain language summary&lt;/h3&gt;\u0000 \u0000 &lt;div&gt;\u0000 \u0000 &lt;ul&gt;\u0000 \u0000 &lt;li&gt;\u0000 \u0000 &lt;p&gt;This study examines the burdens and trends of breast, cervical, ovarian, and uterine cancers among Chinese women from 1990 to 2021.&lt;/p&gt;\u0000 &lt;/li&gt;\u0000 \u0000 &lt;li&gt;\u0000 \u0000 &lt;p&gt;In 2021, breast cancer emer","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular measurable residual disease before transplantation independently predicts survival and relapse risk in adult lysine methyltransferase 2a-rearranged acute myeloid leukemia","authors":"Lulu Wang MD,&nbsp;Yuxiu Chen MD,&nbsp;Mengtong Zang MD,&nbsp;Jianying Zhou MD,&nbsp;Mengyu Xiao MD,&nbsp;Haixia Fu PhD,&nbsp;Xiaodong Mo PhD,&nbsp;Fengrong Wang PhD,&nbsp;Wei Han PhD,&nbsp;Yuanyuan Zhang PhD,&nbsp;Chenhua Yan PhD,&nbsp;Zhidong Wang PhD,&nbsp;Tingting Han PhD,&nbsp;Meng Lv PhD,&nbsp;Huan Chen PhD,&nbsp;Yuhong Chen PhD,&nbsp;Yao Chen PhD,&nbsp;Jingzhi Wang PhD,&nbsp;Yu Wang PhD,&nbsp;Lanping Xu PhD,&nbsp;Kaiyan Liu PhD,&nbsp;Xiaojun Huang PhD,&nbsp;Xiaohui Zhang PhD","doi":"10.1002/cncr.35717","DOIUrl":"10.1002/cncr.35717","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Patients with lysine methyltransferase 2a (<i>KMT2A</i>)-rearranged (<i>KMT2A</i>-r) acute myeloid leukemia (AML) are assigned to intermediate-risk and adverse-risk categories at diagnosis. However, the value of molecular measurable residual disease (MRD) status in patients who have <i>KMT2A</i>-r AML before allogeneic hematopoietic stem cell transplantation (allo-HSCT) in adult cohorts has rarely been evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with <i>KMT2A</i>-r AML who achieved complete remission and subsequently underwent allo-HSCT between January 2015 and January 2023 were included in this analysis. Real-time quantitative polymerase chain reaction was used to detect molecular MRD in bone marrow samples. The end points were overall survival (OS), leukemia-free survival (LFS), the cumulative incidence of relapse (CIR), and nonrelapse mortality (NRM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Pretransplantation molecular MRD was identified in 52 of 125 patients (42%) with <i>KMT2A</i>-r AML. The presence of <i>KMT2A</i>-r MRD was associated with inferior 3-year OS (51% vs. 82%; <i>p</i> &lt; .001), LFS (42% vs. 81%; <i>p</i> &lt; .001), CIR (33% vs. 12%; <i>p</i> &lt; .001), and NRM (11% vs. 5%; <i>p</i> = .12). In multivariate models, molecular MRD status before transplantation independently predicted OS, LFS, and CIR. The survival of adult patients with <i>KMT2A</i>-r AML was heterogeneous, depending on the <i>KMT2A</i> translocation partners, and was more favorable in patients who had t(9;11) and t(10;11) than in those who had t(11;19) and t(6;11). In addition, flow cytometry-based MRD analysis conferred no additional prognostic value to the results of molecular MRD status.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Residual <i>KMT2A</i>-r before allo-HSCT independently predicts the risk of survival and relapse, and donor lymphocyte infusion or posttransplantation maintenance therapies should be considered for patients who have AML with detectable molecular MRD.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial/ethnic differences in trends of testicular germ cell tumor incidence in the United States, 1992–2021","authors":"Andrea A. Almeida MA, MPH,&nbsp;Aika Wojt MS,&nbsp;Catherine Metayer PhD, MD,&nbsp;Peter A. Kanetsky PhD, MPH,&nbsp;Barry I. Graubard PhD,&nbsp;Christian S. Alvarez PhD, MPH,&nbsp;Katherine A. McGlynn PhD, MPH","doi":"10.1002/cncr.35706","DOIUrl":"10.1002/cncr.35706","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Testicular germ cell tumors (TGCTs) are the most common cancers among young men in the United States. Incidence rates among non-Hispanic White (NHW) men historically have been much higher than the rates among other men. To study whether this pattern had changed, the authors examined trends in TGCT incidence for the years 1992–2021.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>By using the Surveillance, Epidemiology, and End Results 12 registries database, age-standardized incidence rates per 100,000 person-years and 95% confidence intervals (CIs) were calculated overall and by histologic type (seminoma and nonseminoma), age, stage at diagnosis, and race/ethnicity. Trends in 5-year survival also were examined.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The age-standardized incidence rate of TGCT per 100,000 person-years increased from 4.71 (95% CI, 4.39–5.05) in 1992 to 6.22 (95% CI, 5.88–6.58) in 2021. The rates increased for both seminoma (average annual percent change [AAPC], 0.57%; 95% CI, 0.40%–0.75%) and nonseminoma (AAPC, 1.41%; 95% CI, 1.17%–1.64%) and among all race/ethnic groups, although the rates stabilized among NHW men. Increases in incidence were greatest among Hispanic men (AAPC, 3.03%; 95% CI, 2.66%–3.40%), who had one of the youngest median ages at diagnosis and were more likely to be diagnosed at advanced stages compared with NHW men. Seminoma and nonseminoma rates among Hispanic men converged over the study period, whereas seminoma rates remained higher among most other groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Hispanic men now have the highest TGCT incidence rates in the United States, although the rates increased among all groups between 1992 and 2021. Racial/ethnic differences in rates require further investigation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":138,"journal":{"name":"Cancer","volume":"131 2","pages":""},"PeriodicalIF":6.1,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35706","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142930113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}